Balsa, Alejandro http://orcid.org/0000-0001-8070-7062
Wassenberg, Siegfried
Tanaka, Yoshiya http://orcid.org/0000-0002-0807-7139
Tournadre, Anne http://orcid.org/0000-0002-5025-0214
Orzechowski, Hans-Dieter http://orcid.org/0000-0001-7374-6899
Rajendran, Vijay
Lendl, Udo
Stiers, Pieter-Jan
Watson, Chris http://orcid.org/0009-0007-9887-6092
Caporali, Roberto
Galloway, James http://orcid.org/0000-0002-1230-2781
Verschueren, Patrick http://orcid.org/0000-0002-0340-3580
Clinical trials referenced in this document:
Documents that mention this clinical trial
POS0704 EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE, WITH 4 OR <4 POOR PROGNOSTIC FACTORS: A POST HOC ANALYSIS OF THE FINCH 1 STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.5051
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-023-00599-1
POS0518 EFFECT OF FILGOTINIB (FIL) ON BODY WEIGHT (BW) AND BODY MASS INDEX (BMI) AND EFFECT OF BASELINE BMI ON THE EFFICACY AND SAFETY OF FIL IN RHEUMATOID ARTHRITIS (RA)
https://doi.org/10.1136/annrheumdis-2022-eular.1088
OP0100 MOLECULAR PROFILING OF PERIPHERAL IMMUNE CELL SUBSETS IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2020-eular.3967
THU0198 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS
https://doi.org/10.1136/annrheumdis-2020-eular.276
Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
https://doi.org/10.1007/s40744-022-00503-3
POS0660 CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.933
POS0679 CLINICAL OUTCOMES UP TO WEEK (W) 48 IN THE ONGOING FILGOTINIB (FIL) LONG-TERM EXTENSION (LTE) TRIAL OF RHEUMATOID ARTHRITIS (RA) PATIENTS (pts) WITH INADEQUATE RESPONSE (IR) TO METHOTREXATE (MTX) INITIALLY TREATED WITH FIL OR ADALIMUMAB (ADA) DURING THE PHASE 3 PARENT STUDY (PS)
https://doi.org/10.1136/annrheumdis-2022-eular.1641
AB0290 EFFECT OF FILGOTINIB ON PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE PHASE 3 FINCH 1, 2 AND 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.1316
POS0844 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WITH A MAXIMUM EXPOSURE OF 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1553
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
https://doi.org/10.1136/annrheumdis-2021-221051
Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
https://doi.org/10.1007/s40744-023-00583-9
Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis
https://doi.org/10.1007/s40744-023-00619-0
THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.267
FRI0136 PERIPHERAL PROTEIN BIOMARKER CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH PRIOR INADEQUATE RESPONSE TO METHOTREXATE (FINCH1)
https://doi.org/10.1136/annrheumdis-2020-eular.4704
POS0824 CARDIOVASCULAR (CV) AND MALIGNANCY EVENTS IN THE FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) CLINICAL DEVELOPMENT PROGRAM UP TO 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1425
FRI0128 FILGOTINIB PROVIDED RAPID AND SUSTAINED IMPROVEMENTS IN FUNCTIONAL STATUS, PAIN, HEALTH-RELATED QUALITY OF LIFE, AND FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM THE FINCH 1 STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.2882
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
https://doi.org/10.1136/ard-2024-225759
POS0051 AN UPDATE ON THE INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS OVER A MEDIAN OF 4.3 YEARS
https://doi.org/10.1136/annrheumdis-2024-eular.1977
POS0526 SEXUAL FUNCTION IN MALE AND FEMALE PATIENTS WITH RHEUMATOID ARTHRITIS: A POST-HOC ANALYSIS OF THE FINCH STUDIES
https://doi.org/10.1136/annrheumdis-2021-eular.1774
THU0215 WHOLE BLOOD TRANSCRIPTIONAL CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH PRIOR INADEQUATE RESPONSE TO METHOTREXATE (FINCH1)
https://doi.org/10.1136/annrheumdis-2020-eular.2996
POS0446 FILGOTINIB-TREATED RHEUMATOID ARTHRITIS PATIENTS WITH HIGH BASELINE NEUTROPHIL-TO-LYMPHOCYTE RATIO SHOW BETTER CLINICAL RESPONSE RATES AND PATIENT-REPORTED OUTCOMES
https://doi.org/10.1136/annrheumdis-2021-eular.850
Impact of filgotinib on pain control in the phase 3 FINCH studies
https://doi.org/10.1136/rmdopen-2023-003839
POS0853 EFFICACY OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA): WEEK (W) 156 RESULTS FROM A LONG-TERM EXTENSION (LTE) STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3572
POS0664 RADIOGRAPHIC CHANGE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ESTIMATED BASELINE YEARLY PROGRESSION ≥5 OR <5: POST HOC ANALYSIS OF TWO PHASE 3 TRIALS OF FILGOTINIB
https://doi.org/10.1136/annrheumdis-2022-eular.198
POS0536 FILGOTINIB DEMONSTRATES CLINICAL EFFICACY IN RHEUMATOID ARTHRITIS INDEPENDENT OF SMOKING STATUS: A POST-HOC SUBGROUP ANALYSIS OF THREE PHASE 3 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.2128
AB0689 SUSTAINED PATIENT MEANINGFUL OUTCOMES OF PAIN AND FATIGUE RELIEF AND IMPROVED PHYSICAL FUNCTIONING WITH FILGOTINIB IN RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS
https://doi.org/10.1136/annrheumdis-2024-eular.2864
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-022-00494-1
POS0843 DISTINCT TREATMENT RESPONSES IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING FILGOTINIB 200 MG OVER 12 MONTHS: A POST HOC ANALYSIS OF FINCH 1
https://doi.org/10.1136/annrheumdis-2023-eular.1318
POS0308 LONG-TERM CLINICAL PROFILE OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA) BY CARDIOVASCULAR (CV) RISK FACTORS: A POST HOC SUBGROUP ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.1552
POS0235 INTEGRATED SAFETY ANALYSIS UPDATE FOR FILGOTINIB (FIL) IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) RECEIVING TREATMENT OVER A MEDIAN OF 2.2 YEARS (Y)
https://doi.org/10.1136/annrheumdis-2022-eular.1631
THU0194 CHARACTERISATION OF DEPTH OF RESPONSE, INCLUDING 50% IMPROVEMENT IN ACR COMPONENTS AT WEEK 12 AND REMISSION AT WEEK 24, FOLLOWING TREATMENT WITH FILGOTINIB COMPARED WITH METHOTREXATE OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2020-eular.2236
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
https://doi.org/10.1136/annrheumdis-2020-219214
Documents that mention this clinical trial
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-023-00599-1
POS0518 EFFECT OF FILGOTINIB (FIL) ON BODY WEIGHT (BW) AND BODY MASS INDEX (BMI) AND EFFECT OF BASELINE BMI ON THE EFFICACY AND SAFETY OF FIL IN RHEUMATOID ARTHRITIS (RA)
https://doi.org/10.1136/annrheumdis-2022-eular.1088
POS0660 CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.933
AB0290 EFFECT OF FILGOTINIB ON PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE PHASE 3 FINCH 1, 2 AND 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.1316
POS0844 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WITH A MAXIMUM EXPOSURE OF 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1553
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
https://doi.org/10.1136/annrheumdis-2021-221051
Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis
https://doi.org/10.1007/s40744-023-00619-0
THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.267
FRI0139 FILGOTINIB PROVIDED RAPID AND SUSTAINED RELIEF OF PAIN AND FATIGUE AND IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DMARDS: RESULTS FROM THE FINCH 2 STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.2901
POS0824 CARDIOVASCULAR (CV) AND MALIGNANCY EVENTS IN THE FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) CLINICAL DEVELOPMENT PROGRAM UP TO 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1425
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
https://doi.org/10.1136/ard-2024-225759
POS0051 AN UPDATE ON THE INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS OVER A MEDIAN OF 4.3 YEARS
https://doi.org/10.1136/annrheumdis-2024-eular.1977
FRI0154 SAFETY AND EFFICACY OF FILGOTINIB IN PATIENTS AGED 65 YEARS AND OLDER: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR)
https://doi.org/10.1136/annrheumdis-2019-eular.2121
AB0448 SAFETY AND EFFICACY OF FILGOTINIB IN JAPANESE PATIENTS ENROLLED IN A GLOBAL PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DMARDS
https://doi.org/10.1136/annrheumdis-2019-eular.2123
POS0526 SEXUAL FUNCTION IN MALE AND FEMALE PATIENTS WITH RHEUMATOID ARTHRITIS: A POST-HOC ANALYSIS OF THE FINCH STUDIES
https://doi.org/10.1136/annrheumdis-2021-eular.1774
THU0204 A SUBGROUP ANALYSIS OF LOW DISEASE ACTIVITY AND REMISSION FROM PHASE 3 STUDY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DMARDS
https://doi.org/10.1136/annrheumdis-2020-eular.2237
AB0394 CLINICAL OUTCOMES UP TO WEEK 48 OF ONGOING FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) LONG-TERM EXTENSION (LTE) TRIAL OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG (bDMARD) INADEQUATE RESPONDERS (IR) INITIALLY ON FIL OR PLACEBO IN A PHASE 3 PARENT STUDY (PS)
https://doi.org/10.1136/annrheumdis-2022-eular.1624
POS0446 FILGOTINIB-TREATED RHEUMATOID ARTHRITIS PATIENTS WITH HIGH BASELINE NEUTROPHIL-TO-LYMPHOCYTE RATIO SHOW BETTER CLINICAL RESPONSE RATES AND PATIENT-REPORTED OUTCOMES
https://doi.org/10.1136/annrheumdis-2021-eular.850
Impact of filgotinib on pain control in the phase 3 FINCH studies
https://doi.org/10.1136/rmdopen-2023-003839
POS0853 EFFICACY OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA): WEEK (W) 156 RESULTS FROM A LONG-TERM EXTENSION (LTE) STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3572
POS0536 FILGOTINIB DEMONSTRATES CLINICAL EFFICACY IN RHEUMATOID ARTHRITIS INDEPENDENT OF SMOKING STATUS: A POST-HOC SUBGROUP ANALYSIS OF THREE PHASE 3 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.2128
AB0689 SUSTAINED PATIENT MEANINGFUL OUTCOMES OF PAIN AND FATIGUE RELIEF AND IMPROVED PHYSICAL FUNCTIONING WITH FILGOTINIB IN RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS
https://doi.org/10.1136/annrheumdis-2024-eular.2864
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-022-00494-1
POS0308 LONG-TERM CLINICAL PROFILE OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA) BY CARDIOVASCULAR (CV) RISK FACTORS: A POST HOC SUBGROUP ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.1552
POS0235 INTEGRATED SAFETY ANALYSIS UPDATE FOR FILGOTINIB (FIL) IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) RECEIVING TREATMENT OVER A MEDIAN OF 2.2 YEARS (Y)
https://doi.org/10.1136/annrheumdis-2022-eular.1631
Documents that mention this clinical trial
POS0518 EFFECT OF FILGOTINIB (FIL) ON BODY WEIGHT (BW) AND BODY MASS INDEX (BMI) AND EFFECT OF BASELINE BMI ON THE EFFICACY AND SAFETY OF FIL IN RHEUMATOID ARTHRITIS (RA)
https://doi.org/10.1136/annrheumdis-2022-eular.1088
OP0100 MOLECULAR PROFILING OF PERIPHERAL IMMUNE CELL SUBSETS IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2020-eular.3967
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-023-00599-1
Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
https://doi.org/10.1007/s40744-022-00503-3
POS0660 CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.933
AB0290 EFFECT OF FILGOTINIB ON PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE PHASE 3 FINCH 1, 2 AND 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.1316
POS0844 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WITH A MAXIMUM EXPOSURE OF 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1553
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
https://doi.org/10.1136/annrheumdis-2021-221051
Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis
https://doi.org/10.1007/s40744-023-00619-0
THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.267
SAT0155 WHOLE BLOOD TRANSCRIPTIONAL CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN MTX-NAÏVE ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) (FINCH3)
https://doi.org/10.1136/annrheumdis-2020-eular.3949
POS0824 CARDIOVASCULAR (CV) AND MALIGNANCY EVENTS IN THE FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) CLINICAL DEVELOPMENT PROGRAM UP TO 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1425
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
https://doi.org/10.1136/ard-2024-225759
POS0051 AN UPDATE ON THE INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS OVER A MEDIAN OF 4.3 YEARS
https://doi.org/10.1136/annrheumdis-2024-eular.1977
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate
monotherapy in patients with active rheumatoid arthritis and limited or no prior
exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
https://doi.org/10.1136/annrheumdis-2020-219213
POS0526 SEXUAL FUNCTION IN MALE AND FEMALE PATIENTS WITH RHEUMATOID ARTHRITIS: A POST-HOC ANALYSIS OF THE FINCH STUDIES
https://doi.org/10.1136/annrheumdis-2021-eular.1774
THU0188 EFFICACY OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH POOR PROGNOSTIC FACTORS: POST HOC ANALYSIS OF FINCH 3
https://doi.org/10.1136/annrheumdis-2020-eular.288
THU0216 PERIPHERAL PROTEIN BIOMARKER CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN METHOTREXATE NAÏVE ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS (FINCH3)
https://doi.org/10.1136/annrheumdis-2020-eular.4725
SAT0158 EFFICACY AND SAFETY OF FILGOTINIB IN METHOTREXATE-NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS: FINCH 3 52-WEEK RESULTS
https://doi.org/10.1136/annrheumdis-2020-eular.277
POS0446 FILGOTINIB-TREATED RHEUMATOID ARTHRITIS PATIENTS WITH HIGH BASELINE NEUTROPHIL-TO-LYMPHOCYTE RATIO SHOW BETTER CLINICAL RESPONSE RATES AND PATIENT-REPORTED OUTCOMES
https://doi.org/10.1136/annrheumdis-2021-eular.850
Impact of filgotinib on pain control in the phase 3 FINCH studies
https://doi.org/10.1136/rmdopen-2023-003839
POS0664 RADIOGRAPHIC CHANGE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ESTIMATED BASELINE YEARLY PROGRESSION ≥5 OR <5: POST HOC ANALYSIS OF TWO PHASE 3 TRIALS OF FILGOTINIB
https://doi.org/10.1136/annrheumdis-2022-eular.198
POS0678 CLINICAL OUTCOMES OF METHOTREXATE (MTX)-NAIVE RHEUMATOID ARTHRITIS (RA) PATIENTS (pts) ON FILGOTINIB (FIL) LONG-TERM EXTENSION (LTE) TRIAL INITIALLY ON FIL OR MTX DURING THE PHASE 3 PARENT STUDY (PS)
https://doi.org/10.1136/annrheumdis-2022-eular.1638
FRI0115 FILGOTINIB PROVIDED RAPID AND SUSTAINED IMPROVEMENTS IN FUNCTIONAL STATUS, PAIN, AND HEALTH-RELATED QUALITY OF LIFE, AND REDUCED FATIGUE OVER TIME IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ARE METHOTREXATE-NAÏVE: RESULTS FROM THE FINCH 3 STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.2927
POS0536 FILGOTINIB DEMONSTRATES CLINICAL EFFICACY IN RHEUMATOID ARTHRITIS INDEPENDENT OF SMOKING STATUS: A POST-HOC SUBGROUP ANALYSIS OF THREE PHASE 3 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.2128
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-022-00494-1
POS0308 LONG-TERM CLINICAL PROFILE OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA) BY CARDIOVASCULAR (CV) RISK FACTORS: A POST HOC SUBGROUP ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.1552
POS0235 INTEGRATED SAFETY ANALYSIS UPDATE FOR FILGOTINIB (FIL) IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) RECEIVING TREATMENT OVER A MEDIAN OF 2.2 YEARS (Y)
https://doi.org/10.1136/annrheumdis-2022-eular.1631
THU0194 CHARACTERISATION OF DEPTH OF RESPONSE, INCLUDING 50% IMPROVEMENT IN ACR COMPONENTS AT WEEK 12 AND REMISSION AT WEEK 24, FOLLOWING TREATMENT WITH FILGOTINIB COMPARED WITH METHOTREXATE OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2020-eular.2236
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
https://doi.org/10.1136/rmdopen-2021-001621
Documents that mention this clinical trial
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-023-00599-1
POS0660 CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.933
POS0679 CLINICAL OUTCOMES UP TO WEEK (W) 48 IN THE ONGOING FILGOTINIB (FIL) LONG-TERM EXTENSION (LTE) TRIAL OF RHEUMATOID ARTHRITIS (RA) PATIENTS (pts) WITH INADEQUATE RESPONSE (IR) TO METHOTREXATE (MTX) INITIALLY TREATED WITH FIL OR ADALIMUMAB (ADA) DURING THE PHASE 3 PARENT STUDY (PS)
https://doi.org/10.1136/annrheumdis-2022-eular.1641
POS0844 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WITH A MAXIMUM EXPOSURE OF 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1553
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
https://doi.org/10.1136/annrheumdis-2021-221051
THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.267
POS0513 SAFETY OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: ANALYSIS OF LYMPHOCYTES IN THE LONG-TERM EXTENSION FINCH 4 STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.888
POS0824 CARDIOVASCULAR (CV) AND MALIGNANCY EVENTS IN THE FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) CLINICAL DEVELOPMENT PROGRAM UP TO 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1425
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
https://doi.org/10.1136/ard-2024-225759
POS0051 AN UPDATE ON THE INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS OVER A MEDIAN OF 4.3 YEARS
https://doi.org/10.1136/annrheumdis-2024-eular.1977
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate
monotherapy in patients with active rheumatoid arthritis and limited or no prior
exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
https://doi.org/10.1136/annrheumdis-2020-219213
AB0454 SAFETY OF FILGOTINIB IN PATIENTS WITH RA: LABORATORY ANALYSIS RESULTS FROM A LONG-TERM EXTENSION STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.2129
AB0394 CLINICAL OUTCOMES UP TO WEEK 48 OF ONGOING FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) LONG-TERM EXTENSION (LTE) TRIAL OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG (bDMARD) INADEQUATE RESPONDERS (IR) INITIALLY ON FIL OR PLACEBO IN A PHASE 3 PARENT STUDY (PS)
https://doi.org/10.1136/annrheumdis-2022-eular.1624
POS0676 EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS AGED ≥75 YEARS: A POST HOC SUBGROUP ANALYSIS OF THE FINCH 4 LONG-TERM EXTENSION (LTE) STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.1563
POS0853 EFFICACY OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA): WEEK (W) 156 RESULTS FROM A LONG-TERM EXTENSION (LTE) STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3572
POS0678 CLINICAL OUTCOMES OF METHOTREXATE (MTX)-NAIVE RHEUMATOID ARTHRITIS (RA) PATIENTS (pts) ON FILGOTINIB (FIL) LONG-TERM EXTENSION (LTE) TRIAL INITIALLY ON FIL OR MTX DURING THE PHASE 3 PARENT STUDY (PS)
https://doi.org/10.1136/annrheumdis-2022-eular.1638
POS0235 INTEGRATED SAFETY ANALYSIS UPDATE FOR FILGOTINIB (FIL) IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) RECEIVING TREATMENT OVER A MEDIAN OF 2.2 YEARS (Y)
https://doi.org/10.1136/annrheumdis-2022-eular.1631
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-022-00494-1
POS0663 THE USE OF EXPOSURE-ADJUSTED EVENT RATES VERSUS EXPOSURE-ADJUSTED INCIDENCE RATES IN ADVERSE EVENT REPORTING: INSIGHTS FROM FILGOTINIB INTEGRATED SAFETY DATA IN RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2022-eular.138
POS0308 LONG-TERM CLINICAL PROFILE OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA) BY CARDIOVASCULAR (CV) RISK FACTORS: A POST HOC SUBGROUP ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.1552
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
https://doi.org/10.1136/annrheumdis-2020-219214
Documents that mention this clinical trial
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-023-00599-1
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
https://doi.org/10.1136/annrheumdis-2016-210104
POS0660 CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.933
POS0844 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WITH A MAXIMUM EXPOSURE OF 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1553
POS0829 SAFETY AND EFFICACY OF FILGOTINIB: AN UPDATE FROM THE DARWIN 3 PHASE 2 LONG-TERM EXTENSION WITH A MAXIMUM OF 8.2 YEARS OF EXPOSURE
https://doi.org/10.1136/annrheumdis-2023-eular.3508
POS0824 CARDIOVASCULAR (CV) AND MALIGNANCY EVENTS IN THE FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) CLINICAL DEVELOPMENT PROGRAM UP TO 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1425
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
https://doi.org/10.1136/ard-2024-225759
POS0051 AN UPDATE ON THE INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS OVER A MEDIAN OF 4.3 YEARS
https://doi.org/10.1136/annrheumdis-2024-eular.1977
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-022-00494-1
POS0308 LONG-TERM CLINICAL PROFILE OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA) BY CARDIOVASCULAR (CV) RISK FACTORS: A POST HOC SUBGROUP ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.1552
Documents that mention this clinical trial
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-023-00599-1
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
https://doi.org/10.1136/annrheumdis-2021-221051
POS0660 CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.933
POS0844 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WITH A MAXIMUM EXPOSURE OF 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1553
POS0829 SAFETY AND EFFICACY OF FILGOTINIB: AN UPDATE FROM THE DARWIN 3 PHASE 2 LONG-TERM EXTENSION WITH A MAXIMUM OF 8.2 YEARS OF EXPOSURE
https://doi.org/10.1136/annrheumdis-2023-eular.3508
THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.267
POS0824 CARDIOVASCULAR (CV) AND MALIGNANCY EVENTS IN THE FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) CLINICAL DEVELOPMENT PROGRAM UP TO 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1425
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
https://doi.org/10.1136/ard-2024-225759
POS0051 AN UPDATE ON THE INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS OVER A MEDIAN OF 4.3 YEARS
https://doi.org/10.1136/annrheumdis-2024-eular.1977
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
https://doi.org/10.1136/annrheumdis-2016-210105
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-022-00494-1
POS0308 LONG-TERM CLINICAL PROFILE OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA) BY CARDIOVASCULAR (CV) RISK FACTORS: A POST HOC SUBGROUP ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.1552
POS0235 INTEGRATED SAFETY ANALYSIS UPDATE FOR FILGOTINIB (FIL) IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) RECEIVING TREATMENT OVER A MEDIAN OF 2.2 YEARS (Y)
https://doi.org/10.1136/annrheumdis-2022-eular.1631
Documents that mention this clinical trial
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-023-00599-1
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
https://doi.org/10.1136/annrheumdis-2021-221051
POS0660 CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.933
POS0844 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WITH A MAXIMUM EXPOSURE OF 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1553
POS0829 SAFETY AND EFFICACY OF FILGOTINIB: AN UPDATE FROM THE DARWIN 3 PHASE 2 LONG-TERM EXTENSION WITH A MAXIMUM OF 8.2 YEARS OF EXPOSURE
https://doi.org/10.1136/annrheumdis-2023-eular.3508
THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.267
POS0824 CARDIOVASCULAR (CV) AND MALIGNANCY EVENTS IN THE FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) CLINICAL DEVELOPMENT PROGRAM UP TO 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1425
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate
monotherapy in patients with active rheumatoid arthritis and limited or no prior
exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
https://doi.org/10.1136/annrheumdis-2020-219213
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
https://doi.org/10.1136/ard-2024-225759
POS0051 AN UPDATE ON THE INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS OVER A MEDIAN OF 4.3 YEARS
https://doi.org/10.1136/annrheumdis-2024-eular.1977
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-022-00494-1
POS0308 LONG-TERM CLINICAL PROFILE OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA) BY CARDIOVASCULAR (CV) RISK FACTORS: A POST HOC SUBGROUP ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.1552
POS0235 INTEGRATED SAFETY ANALYSIS UPDATE FOR FILGOTINIB (FIL) IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) RECEIVING TREATMENT OVER A MEDIAN OF 2.2 YEARS (Y)
https://doi.org/10.1136/annrheumdis-2022-eular.1631
POS0663 THE USE OF EXPOSURE-ADJUSTED EVENT RATES VERSUS EXPOSURE-ADJUSTED INCIDENCE RATES IN ADVERSE EVENT REPORTING: INSIGHTS FROM FILGOTINIB INTEGRATED SAFETY DATA IN RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2022-eular.138
Funding for this research was provided by:
Gilead Sciences
Galapagos NV
Article History
Received: 6 July 2023
Accepted: 5 September 2023
First Online: 25 September 2023
Declarations
:
: Alejandro Balsa has received grants/research support from AbbVie, Pfizer and UCB; worked as a paid consultant for AbbVie, Galapagos, Lilly, Nordic, Pfizer and UCB; and has been paid as a speaker for AbbVie, Galapagos, Gilead, Lilly, Nordic, Pfizer, Sandoz and UCB. Siegfried Wassenberg has received grants/research support from Pfizer; worked as a paid consultant for Galapagos, Lilly and UCB; and has been paid as a speaker for AbbVie, Medac, MSD and Pfizer. Yoshiya Tanaka received speaker fees and/or honoraria from AbbVie, AstraZeneca, Boehringer-Ingelheim, BMS, Chugai, Eisai, Eli Lilly, Gilead, GlaxoSmithKline, Pfizer, Taiho, and Taisho and received research grants from Chugai, Eisai, Mitsubishi-Tanabe Taisho. Anne Tournadre has received grants/research support from Novartis, Pfizer and UCB; worked as a paid consultant for AbbVie, Fresenius Kabi, Lilly, Novartis and Sanofi; and has been paid as an instructor for Fresenius Kabi, and as a speaker for Fresenius Kabi, Lilly, MSD and Sanofi. Hans-Dieter Orzechowski is a former employee of Galapagos and a shareholder in Gilead; Udo Lendl is an employee of Galapagos; Pieter-Jan Stiers is a former employee of Galapagos; Vijay Rajendran and Chris Watson are employees at, and shareholders in, Galapagos. Roberto Caporali worked as a paid consultant, and has been paid as a speaker, for AbbVie, Accord, BMS, Celltrion, Fresenius Kabi, Galapagos, Lilly, MSD, Novartis, Pfizer, Sandoz and UCB. James Galloway has worked as a paid consultant for AbbVie, Galapagos, Gilead, Janssen, Lilly, Novartis and Pfizer; has received grant/research support from AstraZeneca, Celgene, Gilead, Jansen, Medicago, Novavax and Pfizer; has received speaker fees/honoraria from AbbVie, Biogen, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche and UCB. Patrick Verschueren has received institutional grants/research support from Galapagos (Galapagos Chair in Rheumatoid Arthritis at KU Leuven, Belgium, outside the scope of the current study) and Pfizer (Pfizer Chair Management of Early Rheumatoid Arthritis at KU Leuven, Belgium); worked as a paid consultant for AbbVie, BMS, Celltrion, Eli Lilly, Galapagos, Gilead, Nordic Pharma, Pfizer, Sidekick Health and UCB; and has been paid as a speaker for Eli Lilly, Galapagos, MSD and Roularta.
: All studies were conducted in accordance with the Declaration of Helsinki of 1964, and its later amendments, and approved by the institutional review board or ethics committee; all patients provided written informed consent to participate in the study.